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Abstract We previously demonstrated that cells derived from
the mesenchymal layer of the human amniotic membrane
(hAMSC) and their conditioned medium (CM-hAMSC) mod-
ulate lymphocyte proliferation in a dose-dependent manner. In
order to understand the mechanisms involved in immune regu-
lation exerted by hAMSC, we analyzed the effects of CM-
hAMSC on T-cell polarization towards Th1, Th2, Th17, and
T-regulatory (Treg) subsets. We show that CM-hAMSC equally
suppresses the proliferation of both CD4+ T-helper (Th) and
CD8+ cytotoxic T-lymphocytes. Moreover, we prove that the
CM-hAMSC inhibitory ability affects both central
( C D 4 5 RO + CD 6 2 L + ) a n d e f f e c t o r m em o r y
(CD45RO+CD62L−) subsets. We evaluated the phenotype of
CD4+ cells in the MLR setting and showed that CM-hAMSC
significantly reduced the expression of markers associated to the
Th1 (T-bet+CD119+) and Th17 (RORγt+CD161+) populations,
whi le having no effec t on the Th2 popula t ion
(GATA3+CD193+/GATA3+CD294+cells). T-cell subset modu-
lation was substantiated through the analysis of cytokine release
for 6 days during co-culture with alloreactive T-cells, whereby
we observed a decrease in specific subset-related cytokines,
such as a decrease in pro-inflammatory, Th1-related (TNFα,
IFNγ, IL-1β), Th2 (IL-5, IL-6), Th9 (IL-9), and Th17 (IL-17A,
IL-22). Furthermore, CM-hAMSC significantly induced the
Treg compartment, as shown by an induction of proliferating
CD4+FoxP3+ cells, and an increase of CD25+FoxP3+ and
CD39+FoxP3+ Treg in the CD4+ population. Induction of
Treg cells was corroborated by the increased secretion of
TGF-β. Taken together, these data strengthen the findings re-
garding the immunomodulatory properties of CM-hAMSC de-
rived from human amniotic membrane MSC, and in particular
provide insights into their effect on regulation of T cell
polarization.
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Introduction
The human amniotic membrane, as well as the other perinatal
tissues, have recently attracted much attention in regenerative
medicine applications [1]; indeed they can be easily obtained
in a non-invasive manner from tissues normally discarded
after birth, and they also offer an abundant source for
bank development. The therapeutic potential of the peri-
natal stem cells has been prevalently associated to their
immunomodulatory capacities [2–6] and consequent
paracrine effects, as observed in different animal models of
disease [7–9].
Amongst perinatal tissues, the human amniotic membrane
from term placenta has been recently recognized as a valuable
source of mesenchymal stromal cells, referred to as hAMSC
[10–12]. Interestingly, studies have shown the ability of
hAMSC to interact with and modulate the functions of a wide
variety of immune cells. For example, we and others have
shown that hAMSC can inhibit T cell proliferation in vitro
induced by alloantigens, T-cell receptor cross-linking, or mito-
gens [13–17]. Furthermore, we and others have previously
shown that cells derived from the human amniotic membrane
strongly inhibit the generation, maturation, and function of
monocyte-derived dendritic cells (DCs) in vitro [18, 19]. The
in-vitro anti-inflammatory potential of amniotic cells is in line
with the in vivo findings showing reduction of inflammation
and fibrosis in animal models of disease following the trans-
plantation of cells derived from the amniotic membrane. For
example, therapeutic effects have been observed in bleomycin-
challenged mice as shown by a reduction in lung fibrosis
following treatment with amniotic cells [5, 20]. Moreover,
amniotic cells have been reported to ameliorate prognosis
of autoimmune diseases such as rheumatoid arthritis,
encephalomyelitis [6], and experimental autoimmune myocar-
ditis [21]. Furthermore, the use of amniotic membrane patches
were also able to attenuate disease progression. The transplan-
tation of non-cryopreserved amniotic patches [22], or even
those after cryopreservation [23], were able to improve liver
fibrosis in rats with bile-duct ligation and promote ischemic
heart repair in rats with coronary artery ligation [24].
Interestingly, in these studies therapeutic effects were observed
despite absence or rare presence of transplanted cells in host
tissues. These findings have reinforced their capacity to exert
paracrine effects inducing tissue repair by immunomodulation
rather than cell differentiation [11]. Confirmation that the mol-
ecules released from cells are the key players comes from
studies showing that the conditioned medium exerts the same
anti-inflammatory effects as cells [25, 26]. Evidence suggests
that the conditioned medium obtained from the culture of AM
patches or hAMSC inhibits Tcell proliferation [27], inhibits the
differentiation of monocytes towards DCs, and induces a shift
toward M2-like macrophages [28] as observed with MSC from
other placental regions [29]. The molecules and mechanisms
involved are still unclear, but there are many hypotheses which
also take into consideration what is known on mesenchymal
stromal cells derived from bone marrow, which have been
reported to act through IDO, NO, PGE2, TGF-β, IL-10, HGF
and galectins [30, 31]. Moreover, we have provided evidence
that this effect seems to be mediated by low molecular weight,
non-protein, thermostable compounds present in conditioned
medium, and that prostaglandins are one of the key effector
molecules in the immunomodulatory activity [27]. Arising
from the need to identify key effector molecules is the desire
to understand the cells on which they act, and in turn how they
are impacted. Specifically, even though the anti-proliferative
effects on T cells are now widely accepted, the effects of
hAMSC on the different T cell subpopulations remain to be
clearly addressed. Recent studies report the capacity of amni-
otic mesenchymal stromal cells to regulate T cell subsets in
animal models. For example, systemic administration of
hAMSC has been shown to ameliorate experimental autoim-
mune myocarditis (EAM) via the suppression of Th1/Th17
immunity [21]. Similar mechanisms have been extensively
described for mesenchymal stromal cells obtained from other
sources. For example, treatment with bone marrow MSC was
shown to attenuate cutaneous delayed-type hypersensitivity in
mice and was found to be associated with reduced CD4+ and
CD8+ Tcell infiltration at the challenge site [32]. Moreover, the
treatment of colitic mice (model of inflammatory bowel dis-
ease) with MSC from adipose tissue reduced the Th1 cell
responses and induced T regulatory cells [33], while treatment
with MSC from bone marrow prevented Th1-mediated auto-
immune diabetes mellitus in rats, and was associated with
increased CD4+ and CD8+ FoxP3+ T cells [34]. We have very
recently demonstrated that treatment of mice with collagen-
induced arthritis using cells from the amniotic membrane im-
paired antigen specific Th1/Th17 cell expansion in the lymph
nodes, and generated peripheral antigen-specific T regulatory
cells [6]. Taken together, these studies indicate that amnion-
derived cells and its conditioned medium do indeed act on T
cells. Nevertheless, a basic lack of information regarding the
effects that hAMSCs have on individual T-cell effector subsets
remains. In this study, we set out to clarify the polarization of T
cells by performing detailed in vitro studies on both CD4 and
CD8 lineages and we contribute to the understanding of
the time-dependent effects on the polarization of CD4+




Human term placentas were collected after obtaining written
informed consent according to the guidelines of the Ethical
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Committee of the Catholic Hospital (CEIOC, Parere 16/2012)
and of the Ethical Committee of the Hospital Fondazione
Poliambulanza-Istituto Ospedaliero (Brescia, Italy). The re-
search project was authorized by Centro di Ricerca E. Menni-
Fondazione Poliambulanza.
Isolation of Human Amniotic Mesenchymal Stromal Cells
(hAMSC) and Production of Conditioned Medium
(CM-hAMSC)
Human term placentas were processed immediately after birth
using a previously described protocol [27]. Briefly, the amni-
on was manually separated from the chorion and washed
extensively in PBS (Sigma, St Louis, MO, USA) containing
100U/ml penicillin and 100 mg/ml streptomycin (herein re-
ferred to as P/S, Euroclone, Whetherby, UK) and 2.5 mg/ml
amphotericin B (Lonza, Basel, CH). Afterwards, the amnion
was cut into small pieces (3x3 cm2). Amnion fragments were
sterilized by a brief incubation in PBS+2.5 % Eso Jod
(Esoform, Italy) and 3 min in PBS containing 500U/ml pen-
icillin, 500 mg/ml streptomycin, 12.5 mg/ml amphotericin B
and 1.87 mg/ml Cefamezin (Pfizer, Italy). Sterilized amnion
fragments were then incubated for 9 min at 37 °C in HBSS
(Lonza, Basel, CH) containing 2.5U/ml dispase (Roche,
Mannheim, Germany). The fragments were digested in com-
plete RPMI 1640 medium (Cambrex, Verviers, Belgium)
supplemented with 0.94 mg/ml collagenase (Roche) and
20 mg/ml DNase (Roche) for 2.5–3 hrs at 37 °C. Amnion
epithelium fragments were then removed by low-g cen-
trifugation, mobilized hAMSC were passed through a
100 μm cell strainer and collected by centrifugation.
These cells are referred to as hAMSC, for human
Amniotic Mesenchymal Stromal Cells, and at passage
0 (freshly isolated) are characterized by the expression of
CD90 (80.5±10.7 %), CD13 (84.5±8.7 %), CD73 (66±
6 %), CD44 (57±10 %), CD105 (6±4 %), CD166 (9.3±
6.5 %), CD324 (10.4±6.4 %), CD45 (7.4±2.8 %), CD14 (6
±3 %), and negative for CD34 and CD3.
Conditioned Medium generated from freshly isolated
hAMSC. hAMSC (obtained from amniotic membranes
of at least 30 different donors) were re-suspended in
an opportune volume of UltraCulture serum-free medi-
um (Lonza, Basel, CH) supplemented with P/S, and
plated in 24-well plates at 0.5×105 cells/well in a final
volume of 0.5 ml (referred to as CM-hAMSC). After 5-
days of culture at 37 °C with 5 % CO2, the CM-
hAMSC were collected, centrifuged at 300 g, filtered
through a 0.8 μm sterile filter (Sartorius) and frozen at
−80 °C until use. In order to obtain results that were
less influenced by single donor variability and more
representative of bioactive molecules released by hAMSC,
we pooled 8 to 10 different CM-hAMSC and used them for
each specific analysis.
Purification of T-Lymphocytes and Proliferation Assays
Human peripheral blood mononuclear cells (PBMC) were
obtained from heparinized peripheral blood (PB) or buffy coats
(BC) of healthy donors after Ficoll–Hypaque gradient centrifu-
gation (Sigma, St Louis, MO, USA). The purity of PBMC
preparations was checked by FACS analysis to ensure low
red blood cell (RBC) and polymorphonuclear (PMN) cell
contaminations. T-cells were purified from PBMC by negative
selection using the MACS® system (Pan T Cell Isolation Kit),
(Miltenyi Biotec, Bergisch Gladbach, Germany) according to
the manufacturer’s instructions. Lymphocyte proliferation was
induced either by stimulating Tcells (105/well in 96-well-round
bottom plate) by immobilized anti-CD3 (1μg/ml OKT3) / anti-
CD28 (2.5 μg/ml), or by the co-culture with irradiated alloge-
neic stimulator PBMC in mixed lymphocyte reactions (MLR).
MLR were set up with 105 effector T-lymphocytes and 105 γ-
irradiated (3000 cGy) allogeneic PBMC in round-bottom 96-
well plates (Nunc, Roskilde, Denmark). MLR and T+anti-
CD3/28 were cultured in UltraCulture medium. Responder T-
cell/stimulator cell combinations were chosen on the basis of a
minimum of three human leucocyte antigen (HLA) mis-
matches. T-cells were labeled with CFSE dye using the
CellTrace™ CFSE Cell Proliferation Kit (Invitrogen,
Molecular Probes, USA), according to manufacturer’s instruc-
tions. Tcell proliferation was assessed by flow cytometry and is
expressed as a percentage of CFSE diluting cells (Proliferative
Fraction PF) or as Proliferation Index (PI). The PF represents
the percent of proliferating cells and the PI is the sum of the
cells in all generations divided by the number of original parent
cells present at the start of the experiment. It measures the
increase in cell number in culture over the course of the
experiment and is calculated by using FCS express v4.07
(DeNovo Software) from a cell division model which predicts
a cell doubling as a cell proliferated through each daughter
generation. In order to perform FACS analysis only on the
responder T-cells, γ-irradiated allogeneic stimulator PBMC
were labeled using the CellVue® NIR780 Cell Labeling Kit
(eBiosciences) in order to identify and exclude them from
analysis. To assess the effect of CM-hAMSC on the T cell
subsets, we co-cultured T cells in 50 % CM-hAMSC.
Phenotype Analysis of T-Cell Subsets
The phenotypes of the different Tcell subsets were assessed by
FACS analysis by using a set of cell surface markers, intracel-
lular transcription factors, and secreted cytokines, as reported
in Table 1. After 6 days of co-culture with CM-hAMSC, the
cells derived from MLR experiments were collected and cen-
trifuged at 300 g for 5 min. To improve the efficiency of gating
live cells and decrease non-specific staining of dead cells,
before fixation samples were stained with Zombie NIR
Live/Dead Cell Kit (eBiosciences, San Diego, USA). For
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fixation, 0.05 % freshly-prepared, methanol-free formalde-
hyde (ThermoFisher, Waltham, Massachusetts, USA) was
added to the cells and incubated for 15 min at RT. Cells were
then permeabilized with 0.05 % Saponin/100 mM Tris–HCl
pH 7.4 for 15 min. The surface staining was carried out for
30 min at RTwith the following antibodies: anti-CD4 BV421,
anti-CD4 BV510, anti-CD8 BV510, anti-CD25 PerCP-
Cy™5.5, anti-CD28 BV421, anti-CD45RO PE-CF594, anti-
CD73 BV510, anti-CD119 PE, anti-CTLA-4 APC, anti-
CD161 PE, anti-CD183 PE-Cy™7, anti-CD193 BV510,
anti-CD357 APC, anti-CD294 PerCP-Cy™5.5, anti-GARP
PE (all from Becton Dickinson, Franklin Lakes, New Jersey,
USA) and anti-CD39 PE-Cy™7 (eBiosciences). The staining
of intracellular antigens was performed by incubating the cells
in 0.05 % Saponin/100 mM Tris–HCl pH 7.4 for 1 h with the
following antibodies: anti-FoxP3, anti-Helios PE, anti-T-bet
PE-CF594, anti-GATA3 AlexaFluor®647, anti-RORγt
AlexaFluor®647, anti-TGF-β BV421 (all from Becton
Dickinson, Franklin Lakes, New Jersey, USA).
Detection of Secreted Cytokines
The supernatant fromMLR experiments was collected from day
1 to day 6 of culture, and the quantification of secreted cytokines
was evaluated by using a multiple cytometric beads array sys-
temHuman Th1/Th2/Th9/Th17/Th22 13plex FlowCytoMix kit
(eBiosciences, San Diego, USA), according to the manufac-
turer’s instructions. The following cytokines were measured:
IL-1-β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-13, IL-
17A, IL-22, TNF-α, and IFN-α. The levels of TGF-β and
sIL2R were measured using the FlowCytoMix kit
(eBiosciences, San Diego, USA), according to the manufac-
turer’s instructions. Samples were acquired with a FACSAria
(Becton Dickinson, Franklin Lakes, New Jersey, USA) and
analyzed with FlowCytomix Pro software (eBiosciences, San
Diego, USA)
Statistical Analysis
Statistical analyses were performed by means of unpaired,
two-tailed t-tests using GraphPad Prism 6 Software
(GraphPad Software, San Diego, CA, USA). Results are
represented as mean±standard deviation (SD) or standard
error mean (SEM) as specified in the text. A P-value lower
than 0.05 was considered statistically significant.
Results
The Effects of CM-hAMSC on T-Cell Proliferation
We have previously demonstrated that conditioned medium
generated from the culture of freshly isolated hAMSC (CM-
hAMSC) is able to modulate lymphocyte proliferation in a
dose-dependent manner [27]. Herein we assessed the para-
crine effect of CM-hAMSC on the proliferation of CD4+ and
CD8+ lymphocytes. As shown in Fig. 1, the CM-hAMSC
suppressed the proliferation of both CD4+ T helper (Th) cells
and CD8+ cytotoxic T lymphocytes (CTLs), while CM-
hAMSC per se was not able to stimulate T cells (data not
shown). The paracrine suppressive effects of CM-hAMSC
were observed at different time points of the study in T cells
stimulated by allogeneic PBMC (Fig. 1, top panel), and also
via T cell receptor (TCR) stimulation with anti-CD3/anti-
CD28 (Fig. 1, bottom panel). Specifically, at the end of co-
culture with CM-hAMSC, we observed a 45 and 25 %
decrease of Th proliferation in the allogeneic and TCR
settings, respectively, (Fig. 1, left panel). Moreover, at
the end of co-culture with CM-hAMSC we observed a
50 and 35 % decrease of CTL proliferation in the
allogeneic and TCR settings, respectively, (Fig. 1, right
panel).
The Effects of CM-hAMSC on Memory/Naïve Subsets
We then set out to clarify the effects of CM-hAMSC on CD4
and CD8 subsets in terms of proliferation and phenotype. To
this end, we used CFSE-labeled T cells stimulated by alloge-
neic PBMC (MLR) and we evaluated T cell proliferation after
6 days of culture. T cell proliferation was expressed as a
percentage of CFSE diluting cells (Proliferative Fraction,
PF) and by the Proliferation Index (PI).
Table 1 Markers used to identify T cell subpopulations
Th1 Th2 Th17 Treg
Surface antigens CD4, CD183, CD119 CD4, CD193, CD294 CD4, CD161 CD4, CD25, CD39, CD73, CD152, CD357
Transcription factors T-bet GATA-3 RORγt FoxP3, Helios
Cytokines IL-1β, IL-2, TNF-α, IFN-α,
IL-12p70
IL-4, IL-5, IL-6, IL-10, IL-13 IL-17A, IL-22 TGF-β, sIL2-R
The markers described in the Table were used to identify the different T cell subsets in this study, and are divided into 3 categories: surface antigens,
transcription factors, and cytokines
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Specifically, as shown in Fig. 2, we assessed the prolifera-
tion of CD4 and CD8 T cell subsets, distinguishing their
phenotype on the basis of CD45RO and CD62L as previously
reported [35]: CD4 Effector Memory (CD4 EM),
(CD4+CD45RO+CD62L−), CD4 Central Memory (CD4
CM ) , ( CD 4 + CD 4 5RO +CD 6 2 L + ) , CD 4 N a ï v e
(CD4+CD45RO−CD62L+), CD8 Effector Memory (CD8
EM), (CD8+CD45RO+CD62L−), CD8 Central Memory
(CD8 CM), (CD8+CD45RO+CD62L+), CD8 Effector (CD8
EMRA), (CD8+CD45RO−CD62L−), and CD8 Naïve
(CD8+CD45RO−CD62L+ cells). We observed that the prolifer-
ation of both CD4 EffectorMemory (Fig. 2B) and CD4 Central
Memory (Fig. 2C) cells are inhibited by the CM-hAMSC.
Specifically, we observed a decrease in both the PF (85 to
74 % [mean±SD: 86.75 %±1.45 to 79.25 %±4.14, p<0.05])
and PI (6.25 to 3.2 [7.37±0.90 to 4.14±0.89, p<0.01]) of the
CD4 Effector Memory cells (Fig. 2B). CD4 Central Memory
cells also showed a reduction in both the PF (from 77 to 47 %
[79.88 %±2.19 to 59.33 %±11.37, p<0.05]) and PI (4.14 to
1.71 [4.54±0.45 to 2.54±0.89, p<0.01]), (Fig. 2C). On the
other hand, the CD4+ Naïve cells did not proliferate and
showed a resting behavior both prior to (PF: 2.3 %, PI: 1.0
[PF: 1.75 %±0.37, PI: 1.0±0.0]) and after (PF: 1.5 %, PI: 1.0
[PF: 1.53 %±0.24, PI: 1.0±0.0]) culture with CM-hAMSC
(Fig. 2D). Similar effects were seen on CD8 subsets where
co-culture with CM-hAMSC inhibited the proliferation of CD8
Effector Memory cells (PF: 79 % vs. 63 %, PI: 4 % vs. 2.3 %
[PF: 80.41 %±1.16 vs. 69.91 %±4.08, p<0.01; PI: 5.01±0.93
vs. 2.71±0.58, p<0.01], Fig. 2E), CD8 Central Memory cells
(PF: 82 % vs. 48 %, PI 4.65 % vs. 1.8 %, [PF: 86.89 %±3.25
vs. 62.91 %±9.37, p<0.01; PI: 7.55±2.19 vs. 2.46±0.66,
p<0.01], Fig. 2F), and CD8 Effector (PF: 25 % vs. 4 %, PI
1.2 % vs. 1 %, [PF: 16.57 %±7.62 vs. 5.45 %±1.45, p<0.05;
PI: 1.08±0.11 vs. 1.00±0.00, p<0.01], Fig. 2G). As observed
in the CD4+ cells, CM-hAMSC had no effect on the prolifer-
ation of CD8 Naïve cells, which had a resting behavior prior to
and after co-culture (PF: 4.6 % vs. 1.5 %, PI 1 % vs. 1 %, [PF:
3.21%±1.15 vs. 1.31%±0.60, p<0.05; PI: 1.00±0.00 vs. 1.00
±0.00], Fig. 2H).
On the basis of the observed inhibitory ability, we also
evaluated how the CM-hAMSC influenced the relative
content/frequency of each T-cell subset described above.
Regarding the CD4 positive cells, we observed a reduction
in the Central Memory compartment, no variation in the
Effector Memory compartment, and a relative increase
of Naïve population (Fig. 2I). Similarly, within the
CD8+ population, we observed a decrease of the
Central Memory and a relative increase of the Naïve
compartment (Fig. 2J). Finally, we observed that in the
presence of CM-hAMSC, the percentage of CD8 Effector
Memory did not change while that of CD8 Effector increased
in the presence of CM-hAMSC (Fig. 2J).
We performed further analysis of T-cell populations
based on their CD28 co-stimulatory molecule expression.
It is known that CD8+ cells can be distinguished into cyto-
toxic CD8+CD28+ and suppressor/regulatory CD8+CD28−
Fig. 1 Inhibitory effects of
CM-hAMSC on CD4+ and CD8+
proliferation. T cell proliferation
was stimulated either with
allogeneic PBMC in mixed
lymphocyte reactions
(MLR, circles in top panel) or by
T cell receptor stimulation using
anti-CD3/CD28 (squares in
bottom panel). Proliferation of
CD4+ (left panel) and CD8+ (right
panel) was measured in the
absence (empty circles/squares)
or presence (black-filled circles/
squares) of conditioned medium
(CM-hAMSC). Data represent the
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subsets [36]. As shown in Fig. 3A (upper panel), the pres-
ence of CM-hAMSC increased the frequency of
CD8+CD28− Tcells, while no difference was observed after
culture with CM-hAMSC in the CD4+CD28− population.
To further characterize the phenotype of the CD8+CD28−
cells, we also evaluated the expression for CD45RO and
CD62L markers. Even though most of CD8+CD28− cells
showed a Naïve phenotype (CD45RO−CD62L+), (Fig. 3B),
we observed a significant increase in the percentage of the
CD8+CD28− population induced by CM-hAMSC within
both the Effector Memory (CD45RO+CD62L−) and the
Central Memory (CD45RO+CD62L+) compartments
(Fig. 3B).
The Effects of CM-hAMSC on T Helper (Th) Differentiation
To assess the effects of bioactive molecules derived from
hAMSCs on the polarization of Th cells, we evaluated the
phenotype of CD4+ cells after 6 days of co-culture. As shown
in Fig. 4, CM-hAMSC by itself did not induce significant
changes in the percentage of cells positive for Th transcription
factors (T-bet, GATA-3, RORγt) in unstimulated T cells. In the
MLR setting, CM-hAMSC significantly reduced CD4+T-bet+
and CD4+RORγt+ cells (Fig. A and 4C) whilst having no effect
on CD4+GATA3+ cells (Fig. 4B). Moreover, CM-hAMSC
caused a 60 % reduction in T-bet+CD183+ cells (Fig. 4D,
p<0.05), which are markers associated to Th1 cells.
Fig. 2 Effects of CM-hAMSC on the proliferation of CD4+ and CD8+
subsets. Panel (A) shows the gating strategy used for analysis. CD4 and
CD8 T cell proliferation in mixed lymphocyte reactions (MLR) or co-
cultured with CM-hAMSC is expressed as a percentage of CFSE diluting
cells (Proliferative Fraction, PF) or by the Proliferation Index (PI). The
following phenotypes were analyzed after 6 days of co-culture: (B) CD4
Effector Memory (EM, CD4+CD45RO+CD62L−); (C) CD4 Central
Memory (CM, CD4+CD45RO+CD62L+); (D ) CD4 Naïve
(CD4+CD45RO−CD62L+); (E) CD8 Effector Memory (EM,
CD8+CD45RO+CD62L−); (F) CD8 Central Memory (CM,
CD8+CD45RO+CD62L+ ) ; (G ) CD8 E f f e c t o r ( EMRA,
CD8+CD45RO−CD62L−); (H) CD8 Naïve (CD8+CD45RO−CD62L+
cells). The frequency of the different subsets (reported as %) gated on
the CD4 (I) and CD8 cells (J). The figure is representative of three
independent experiments which showed statistically significant differ-
ences between MLR-CM-hAMSC and MLR for PF in CD4 CM, CD4
EM, CD8 CM, CD8 EM, CD8 Naïve, CD8 EMRA; and for PI in CD4
CM, CD4 EM, CD8 CM, CD8 EM
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Conversely, co-culture with CM-hAMSC had no effect on the
T-bet+CD119+ subpopulation, also associated to Th1 cells
(Fig. 4D). No changes were observed also for the Th2 popula-
tion, represented by GATA3+CD193+ and GATA3+CD294+
(Fig. 4E). Finally, co-culture with CM-hAMSC caused a 56 %
reduction in RORγt+CD161+, a marker associated to Th17 cells
(Fig. 4F, p<0.05). Taken together, these data demonstrate that
the CM-hAMSC-mediated inhibition of alloreactive T
Fig. 3 CM-hAMSC increases the CD28- population within CD8+ subsets.
Flow cytometry analysis was performed on allostimulated T cells in pres-
ence or absence of CM-hAMSC after 6 days of co-culture. (A) The
percentage of cells expressing CD28 was evaluated in the total CD8+ cells
(upper panels) or in the CD4+ cells (bottom panels). (B) The CD45RO and
CD62L positivity was evaluated by gating on CD8+CD28− cells. Data
represent the mean and SD of at least 3 experiments. Asterisks indicate
statistically significant differences between MLR-CM-hAMSC and MLR;
*p<0.05
Fig. 4 Effects of CM-hAMSC on the T helper polarization. The expres-
sion of the following T helper transcription factors: T-bet+ (Th1) (A)
GATA-3+ (Th2) (B) RORγt+ (Th17) (C) was evaluated on unstimulated
T-cells in absence (T, gray-dotted bars) or presence (T+CM-hAMSC,
lined bars) of CM-hAMSC, and on alloreactive CD4+ cells in the absence
(white bars) or presence (black bars) of CM-hAMSC. The phenotypes of
the different CD4 T helper subsets were assessed by double positive
populations for both Th-specific transcription factors and surface
markers: T-bet+CD183+ and T-bet+CD119+ (Th1) (D), GATA-
3+CD193+ and GATA-3+CD294+ (Th2) (E), RORγt+CD161+ (Th17)
(F), as reported in Table 1. Data represent the mean and SD of at least
five experiments. Asterisks indicate statistically significant differences
between MLR-CM-hAMSC and MLR; *p<0.05
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lymphocytes is associated also with modulation of the Th1 and
Th17 pathway.
The Effects of CM-hAMSC on T Regulatory (Treg) Cells
Based on the evidence of Th polarization exerted by CM-
hAMSC, we sought to analyze the phenotype of induced T
regulatory (Treg) cells. To this aim, we assessed alloreactive
CFSE–labeled responder T cells after 6 days of co-culture in
presence of CM-hAMSC by evaluating the percentage of
CFSE-diluting (i.e. dividing) Tcells. Interestingly, we observed
that CM-hAMSC intensively modulates the Treg compartment
(Fig. 5). First, we observed that CM-hAMSC by itself was not
able to induce the expression of FoxP3, but in the MLR setting
CM-hAMSC significantly increased CD4+FoxP3+ cells
(Fig. 5A). We also observed that the induction of FoxP3 cells
was restricted to proliferating cells (Fig. 5B). As shown in
Fig. 5C, the CM-hAMSC intensively modulates the Treg com-
partment by inducing a five-fold increase of CD25+FoxP3+
cells. We also evaluated the expression of CD39 and CD73 in
Treg and found that the percentage of CD39-expressing Treg in
the CD4+ population markedly increased in the presence of
CM-hAMSC (Fig. 5C). We observe an increase also of the
CD73+ population even though it did not reach significance
(Fig. 5C). Further characterization of cell surface antigens
expressed by the CM-hAMSC-induced Treg cells demonstrat-
ed different patterns of expression when compared with Treg
present in theMLR itself. In particular, we observed an increase
Fig. 5 CM-hAMSC induces T lymphocytes with regulatory phenotype.
(A) The percentage of CD4+FoxP3+ cells in unstimulated T cells in
absence (T, gray-dotted bars) or presence (T+CM-hAMSC, lined bars)
of CM-hAMSC, and in stimulated (MLR) T cells in absence (white bars)
or presence (black bars) of CM-hAMSC. Data represent mean and SD of
5 individual experiments. (B) The percentage of proliferating and FoxP3-
positive cells in the presence or absence of CM-hAMSC. The plot is
representative of 3 experiments. (C) CD4 Treg phenotypes were assessed
by double positive populations for both FoxP3 and surface markers
(CD25, CD39, CD73). Box and whispers plots were generated using
the Tukey method. CD25 Treg and CD39 Treg were characterized by
additional surface markers CTLA-4 (D), GARP (E), CD357 (F), and
intracellular markers such as TGF-β (G) and Helios (H). The release of
TGF-β during 6 days co-culture was evaluated as described in Materials
and Methods, the graph represents the mean and standard error mean
(SEM) of at least four experiments (F). Asterisks indicate statistically
significant differences between MLR+CM-hAMSC and MLR; *p<0.05
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of CTLA-4+ (Fig. 5D) and GARP+ (Fig. 5E) cells within both
CD4+CD25+FoxP3+ and CD4+CD39+FoxP3+ (Fig. 5E).
TGF-β was highly expressed by both CD25+ and CD39+
FoxP3+ Treg cells, but the percentage of TGF-β cells increased
significantly by CM-hAMSC only in the CD39+ FoxP3+ Treg
(Fig. 5G). Conversely, we observed a significant increase of
CD357+ (AITR/GITR) cells only in the CD4+CD25+FoxP3+
population in presence of CM-hAMSC (Fig. 5F). Finally, both
CD4+CD25+FoxP3+ and CD4+CD39+FoxP3+ cells were all
positive for Helios (Fig. 5H). To confirm the induction of
Treg cells, we analyzed the release of TGF-β during 6 days
of co-culture of alloreactive Tcells in presence of CM-hAMSC.
As shown in Fig. 5I, the CM-hAMSC induced the secretion of
TGF-β starting from 3 days of co-culture, and this induction
was significant and consistent over time (p<0.05).
CM-hAMSC Modifies the Secretion of Th-Cytokines
After having studied which Th cells were directly inhibited by
CM-hAMSC, in order to give further insight into the function
of the different T subsets, we studied their cytokine profile. To
this aim, we analyzed cytokine release for 6 days during co-
culture with alloreactive T cells. To assess the modulation of
secreted molecules in the culture medium, we compared the
level of cytokines released from alloreactive T cells in pres-
ence or absence of CM-hAMSC. We also considered the
initial amount of cytokine produced by the CM-hAMSC itself
(white diamond in Fig. 6). As shown in Fig. 6, we analyzed a
panel of cytokines specific for the different T-cell subsets: Th1
(IFN-γ, TNFα, IL-1β, IL-2, IL-12p70), Th2 (IL-4, IL-5, IL-6,
IL-10, IL-13), Th17 (IL-17A, IL-22), and Th9 (IL-9)
(Table 1). For all cytokines analyzed except IL-6, levels in
the CM-hAMSC per se were below levels detected inMLR on
day 1 (Fig. 6). In the presence of CM-hAMSC, the secretion
of the pro-inflammatory Th1-cytokines TNFα and IFNγ was
strongly inhibited starting from 24 to 48 h respectively, and
this inhibition remained constant over time (Fig. 6A). To a
lesser extent, IL-1β also decreased starting from 48 h up to
5 days after the addition of CM-hAMSC (Fig. 6A).
Interestingly, the IL-2 secretion increased over time in the
presence of CM-hAMSC, while the levels of IL-12p70 were
not affected by the addition of CM-hAMSC, which remained
low throughout the time course (Fig. 6A). In regards to the
Th2-cytokines, the secretion of IL-5 and IL-6, was markedly
reduced starting from 24 h of co-culture with CM-hAMSC
(Fig. 6B). As we have previously observed [27], the CM-
hAMSC per se contained high levels of IL-6 (Fig. 6B).
Conversely, the presence of CM-hAMSC induced the secre-
tion of IL-10 starting from 24 h of co-culture, and this induc-
tion decreased over time, while the CM-hAMSC had no effect
on IL-4 secretion over time (Fig. 6B). The CM-hAMSC
induced an increase in the secretion of IL-13 starting from
72 h after co-culture/activation (Fig. 6B). The release of Th17-
cytokines (IL-17A and IL-22) and IL-9, a Th9-related
Fig. 6 CM-hAMSC modulates the secretion of Th cytokines. The secre-
tion of cytokines specific for the different T-cell subsets was evaluated
each day during 6 days of co-culture in absence (white squares) or
presence (black squares) of CM-hAMSC. The amount of cytokine pro-
duced by the CM-hAMSC itself was measured on day one only and is
represented by a white diamond. The quantification of (A) Th1 cytokines
(IFN-γ, TNFα, IL-1β, IL-2, IL-12p70), (B) Th2 cytokines (IL-4, IL-5,
IL-6, IL-10, IL-13), (C) Th17 cytokines (IL-17A, IL-22), (D) IL-9 and
sIL-2R were evaluated as described in Materials and Methods. Data
represent the mean and standard error mean (SEM) of at least three
experiments. Asterisks indicate statistically significant differences be-
tween MLR-CM-hAMSC and MLR; *p<0.05; **p<0.01
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cytokine, were inhibited by the CM-hAMSC, and this inhibi-
tion remained consistent throughout the 6-day observation
period (Fig. 6C and D). Finally, sIL-2R significantly increased
in the presence of CM-hAMSC starting from 3 days after co-
culture and continuing up to the end (day 6), (Fig. 6D,
p<0.05).
Discussion
Increasing evidence indicate that derivatives from the human
amniotic membrane, such as patches, cells, and conditioned
medium derived from these cells, exert therapeutical effects in
diseases associated with altered inflammatory processes [8] or
in autoimmune disorders [6]. The lack or very low engraft-
ment of transplanted cells, and the evidence that conditioned
medium per se is effective, supports the notion that the ther-
apeutic effect is due to bioactive molecules released from
hAMSC that act through a paracrine/endocrine mechanism.
A likely explanation of the beneficial effects exerted by
hAMSC is associated to the immunomodulatory potential of
these cells, a characteristic identified previously in MSC from
other sources, such as bone marrow [37–40]. Indeed, it has been
extensively reported that hAMSC can inhibit T cell proliferation
induced by alloantigens, T-cell receptor cross-linking, or mito-
gens in vitro [13–15, 17, 19] and can inhibit the generation,
maturation and function of monocyte-derived dendritic cells
(DCs) [18, 41]. The confirmation that the molecules released
from cells are the key players in their immunomodulatory effect
comes from the observation that the conditioned medium obtain-
ed from the culture of both AM patches and hAMSC inhibit T
cell proliferation [27], inhibit the differentiation of monocytes
towards DCs and induce a shift toward M2-like macrophages
[28, 29]. Tcells have a prominent role in immune regulation, and
polarization of the different T-cell subsets plays an important role
in controlling the mechanisms of immune response in phenom-
ena like acute and chronic inflammation and autoimmune re-
sponses. Since until now reports which provide evidence that
hAMSC act on T cells are mainly based on the effects on
total T cells and often limited to the proliferative pa-
rameters, we set out to perform a detailed study on the
effects of conditioned medium from hAMSC on both
CD4 and CD8 subsets and on different Th subsets. To this
aim, we analyzed cell proliferation, alterations in phenotype,
and cytokine production in a time-course response.
First, we observed that conditioned medium derived from
hAMSC, when cultured without inflammatory stimuli, sup-
presses the proliferation of both CD4+ Th cells and CD8+
cytotoxic T lymphocytes (CTLs) stimulated by allogeneic
PBMC, and also via T cell receptor (TCR) stimulation with
anti-CD3/anti-CD28. This supports our previous observations
that CM derived from amnion possess anti-proliferative effect
in absence of stimulating culture conditions [27]. This is in
contrast to BM-MSC which possess an anti-proliferative abil-
ity only when cultured in the presence of activating stimuli,
such as IL-1β, TNF-α or IFN-γ [30, 42, 43].
The differentiation of T cells into effector and memory
subsets is one of the key aspects of T cell mediated
immunity. We therefore characterized the effect of
hAMSC on the T-cell response of Naïve and Memory T
cells and demonstrate that CM-hAMSC inhibited the pro-
liferation of both CD4/CD8 Effector Memory and CD4/
CD8 Central Memory cells, while no variation was ob-
served regarding the proliferation of the CD4/CD8 Naïve
T-cell population. Others have shown that bone marrow
MSC are able to equally inhibit the proliferation of
Memory and Naïve T cells using HY peptide-stimulated
splenocytes from transgenic HY-TCRhigh mice [44]. The
relative increase we observed in the percentage of Naïve
cells (CD45RO−CD62L+) after CM-hAMSC co-culture
can be justified by the decrease observed in the other
subsets.
Within the CD8+ population (which drastically decreased
in the presence of CM-hAMSC), we observed an increase of
the CD8+CD28− population. This can be explained by the
preferential survival of this population, as manifested by the
fact that we observed a relative increase of CD8+CD28−
within the Effector Memory, Central Memory, and EMRA
compartments. Interestingly, CD8+CD28− Tcells have been
reported as T regulatory cells [45, 46]. Indeed, CD8+CD28−
T cells have been shown to be accountable for regulatory
functions associated to disease amelioration in an autoim-
munemousemodel [47]. Moreover, they have been reported
to be able to down-regulate the Th reactivity by suppression
of antigen-presenting cells [48], and to be responsible for the
inhibition of both T-cell proliferation and CTL function
[49]. The effect of MSC on the CD8+CD28− population is
still a matter of debate. Indeed, it has been shown that MSC
from adipose tissue induce an inhibition of CD8+CD28−
cells [50], while others, in accordance with our data, have
shown that MSC from bone marrow induce an increase of
this population thus contributing to the attenuation of refrac-
tory dry eye secondary to chronic graft-versus-host-disease
[51].
Within the CD4 population we were able to confirm the
evident anti-inflammatory properties of hAMSC. Indeed our
results showed that CM-hAMSC induced the inhibition of
Th1 (Tbet+CD183+) and Th17 (RORγt+CD161+) subset pro-
liferation, and down-regulated pro-inflammatory Th1 cyto-
kines IFN-γ, TNFα, and IL-1β, and Th17 cytokines such as
IL-17A and IL-22. Even though CM-hAMSC did not influ-
ence Th2 (GATA3+/CD193+ or GATA3+/CD294+) cell expan-
sion, the release of Th2 cytokines, such as IL-5 and IL-6, was
significantly reduced in the presence of CM-hAMSC.
Treg, a subpopulation of CD4+ Tcells commonly identified
by the expression of Forkhead box P3 (FoxP3) transcription
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factor, are key players in the mechanisms that are evoked to
control the immune response. The two main subsets of Treg
are natural Treg, which are thymus-derived and specific for
self-antigens, and adaptive/induced Treg which can be gener-
ated from Naïve CD4+ T cells in peripheral lymphoid
tissues following inflammatory stimuli [52, 53]. Both
bone marrow [37, 54, 55] and adipose tissue [56, 57]-derived
MSC have been extensively studied for their capacity to
induce Treg induction.
The major cytokines responsible for inducing the differen-
tiation of iTregs are IL-2 and TGF-β [58]. In presence of CM-
hAMSC, we observed an increase of IL-2 and soluble form of
CD25 (sCD25 or sIL-2R), and also of TGF-β. These obser-
vations further support T cell differentiation toward the Treg
phenotype in the presence of CM-hAMSC. Tregs are able to
secrete anti-inflammatory cytokines such as TGF-β, IL-10,
IL-13 [59, 60] and these cytokines are known to be critical
factors involved in the suppression of the pro-inflammatory
cytokine response. Indeed, we observed an increase of the
production of TGF-β and IL-13 during the co-culture of
allogeneic activated T cells with CM-hAMSC. In addition to
CD4+CD25+FoxP3+ Tregs, we also observed an increase in
Tregs expressing CD39, suggesting that the adenosynergic
pathway, which has functional relevance for cellular immuno-
regulation [61–63], could also be involved in the immuno-
modulatory functions exerted by CM-hAMSC.
Furthermore, in co-cultures with CM-hAMSC,
CD4+CD25+FoxP3+ and CD4+CD39+FoxP3+ Tregs showed
an increase in percentage of cells positive for Cytolytic T
lymphocyte-associated antigen (CTLA)-4 and Glycoprotein A
Repetitions Predominant (GARP), which have been shown to
selectively identify activated human FoxP3+ regulatory T cells
[64]. CTLA-4 has been shown to participate in Treg-mediated
suppression by inhibition of dendritic cell (DC)-mediated T-cell
stimulation [65, 66]. GITR appears to control DC and mono-
cyte development and in its absence, mice develop aggravated
chronic enterocolitis via an imbalance of colitogenic Th1 cells
and Treg cells [67]. Taken together, these data strongly dem-
onstrate that CM-hAMSC not only induces upregulation of the
Treg population, but also induces Treg functions as shown by
the altered activation of specific surface molecules that could
contribute to the control of the immune suppression.
Interestingly, we demonstrated up-regulation of Treg in the
culture of allogeneic activated T cells in the presence of
conditioned medium derived from unstimulated hAMSC cul-
ture. This is in line with what we previously observed for CM
on total T cell populations [27], and our current observation
regarding CD4 and CD8 subpopulations, as well as for Th1 or
Th17 subsets. These findings also support the in vivo data
showing upregulation of Treg in autoimmune disorders, such
as that seen with PBMC from patients with rheumatoid arthri-
tis after addition of either hAMSC or CM-hAMSC [6]. This is
in contrast to MSC derived from bone marrow, whereby
stimulation with inflammatory cytokines, such as TNFα or
IFNγ, are required in order to have immune regulatory effects
and specifically induce Treg [68, 69].
In conclusion, this study provides new insights regarding
the immune-modulating mechanism of hAMSC associated to
the therapeutical effect observed in pre-clinical in vivomodels
and hypothesized to constitute the basis for their clinical
application. Altogether, these results reinforce the potential
use of these cells, and in particular their conditioned medium,
which could constitute a cell-free treatment in diseases corre-
lated to an altered inflammatory response.
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